- Home
- Products
- Customized ADCs
- ITGB2
- Anti-ITGB2 (Rovelizumab)-MC-MMAF ADC
Anti-ITGB2 (Rovelizumab)-MC-MMAF ADC (CAT#: ADC-W-1504)
This ADC product is comprised of an anti-ITGB2 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- ITGB2
- Alternative Names
- ITGB2; integrin, beta 2 (complement component 3 receptor 3 and 4 subunit); CD18, integrin, beta 2 (antigen CD18 (p95), lymphocyte function associated antigen 1; macrophage antigen 1 (mac 1) beta subunit) , MFI7; integrin beta-2; LFA 1; MAC 1; integrin beta chain, beta 2; complement receptor C3 beta-subunit; complement receptor C3 subunit beta; leukocyte cell adhesion molecule CD18; leukocyte-associated antigens CD18/11A, CD18/11B, CD18/11C; cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta; cell surface adhesion glycoprotein LFA-1/CR3/P150,959 beta subunit precursor); LAD; CD18; MF17; MFI7; LCAMB; LFA-1; MAC-1;
- Target Entrez Gene ID
- 3689
- Target UniProt ID
- P05107
- Overview
- This gene encodes an integrin beta chain, which combines with multiple different alpha chains to form different integrin heterodimers. Integrins are integral cell-surface proteins that participate in cell adhesion as well as cell-surface mediated signalling. The encoded protein plays an important role in immune response and defects in this gene cause leukocyte adhesion deficiency. Alternative splicing results in multiple transcript variants.
- Overview
- Humanized Anti-ITGB2 IgG2 antibody, Rovelizumab
- Generic name
- Rovelizumab
- Host animal
- Mouse
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-TNFRSF10B (Lexatumumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1877)
- Anti-CD37 (Otlertuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-823)
- Anti-IL6 (Sirukumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1409)
- Anti-ITGA4 (Etrolizumab)-SPDB-DM4 ADC (CAT#: ADC-W-1473)
- Anti-NGF (Fulranumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1662)
- Anti-CEACAM1 scFv-dextran T-40-MMC ADC (CAT#: ADC-W-381)
- Anti-CEACAM5 (Altumomab)-SPDB-DM4 ADC (CAT#: ADC-W-969)
- Anti-KDR (Ramucirumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1517)
- Anti-CD4 (Clenoliximab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-881)
- Anti-EGFR (Matuzumab)-SPDB-DM4 ADC (CAT#: ADC-W-1035)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1504. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-1509 | Anti-ITGB2 (Erlizumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-1513 | Anti-ITGB2 (Erlizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-1510 | Anti-ITGB2 (Erlizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-1511 | Anti-ITGB2 (Erlizumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-1503 | Anti-ITGB2 (Rovelizumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-115 | Anti-CD33-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-515 | Anti-EGFR-Mc-MMAF ADC-5 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-114 | Anti-CD33-Mc-MMAF ADC-3 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-485 | Anti-EphA2-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2606 | Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2544 | Anti-CD44 (Bivatuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2591 | Anti-EGFR (Cetuximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-AA-063 | Anti-HIgG(Fab)-N-MMAF ADC | Noncleavable linkers | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
